These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 24279293)

  • 41. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.
    Jimeno A; Rubio-Viqueira B; Amador ML; Oppenheimer D; Bouraoud N; Kulesza P; Sebastiani V; Maitra A; Hidalgo M
    Cancer Res; 2005 Apr; 65(8):3003-10. PubMed ID: 15833824
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pemphigus vulgaris identifies plakoglobin as key suppressor of c-Myc in the skin.
    Williamson L; Raess NA; Caldelari R; Zakher A; de Bruin A; Posthaus H; Bolli R; Hunziker T; Suter MM; Müller EJ
    EMBO J; 2006 Jul; 25(14):3298-309. PubMed ID: 16871158
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New insights into desmosome regulation and pemphigus blistering as a desmosome-remodeling disease.
    Kitajima Y
    Kaohsiung J Med Sci; 2013 Jan; 29(1):1-13. PubMed ID: 23257250
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
    Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
    Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pemphigus vulgaris acantholysis ameliorated by cholinergic agonists.
    Nguyen VT; Arredondo J; Chernyavsky AI; Pittelkow MR; Kitajima Y; Grando SA
    Arch Dermatol; 2004 Mar; 140(3):327-34. PubMed ID: 15023776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Desmoglein 1-negative, desmoglein 3-positive pemphigus herpetiformis with involvement of oral mucous membranes].
    Brod C; Fierlbeck G; Metzler G; Sönnichsen K; Röcken M; Schaller M
    J Dtsch Dermatol Ges; 2005 Apr; 3(4):280-2. PubMed ID: 16370478
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mechanisms of mitochondrial damage in keratinocytes by pemphigus vulgaris antibodies.
    Kalantari-Dehaghi M; Chen Y; Deng W; Chernyavsky A; Marchenko S; Wang PH; Grando SA
    J Biol Chem; 2013 Jun; 288(23):16916-16925. PubMed ID: 23599429
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A spontaneous deletion within the desmoglein 3 extracellular domain of mice results in hypomorphic protein expression, immunodeficiency, and a wasting disease phenotype.
    Kountikov EI; Poe JC; Maclver NJ; Rathmell JC; Tedder TF
    Am J Pathol; 2015 Mar; 185(3):617-30. PubMed ID: 25542773
    [TBL] [Abstract][Full Text] [Related]  

  • 49. p38MAPK inhibition prevents disease in pemphigus vulgaris mice.
    Berkowitz P; Hu P; Warren S; Liu Z; Diaz LA; Rubenstein DS
    Proc Natl Acad Sci U S A; 2006 Aug; 103(34):12855-60. PubMed ID: 16908851
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Defining the involvement of proteinases in pemphigus vulgaris: evidence of matrix metalloproteinase-9 overexpression in experimental models of disease.
    Cirillo N; Lanza M; Rossiello L; Gombos F; Lanza A
    J Cell Physiol; 2007 Jul; 212(1):36-41. PubMed ID: 17311292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ocular involvement in pemphigus vulgaris.
    Akhyani M; Keshtkar-Jafari A; Chams-Davatchi C; Lajevardi V; Beigi S; Aghazadeh N; Rayati Damavandi M; Arami S
    J Dermatol; 2014 Jul; 41(7):618-21. PubMed ID: 24985543
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evidence of key role of Cdk2 overexpression in pemphigus vulgaris.
    Lanza A; Cirillo N; Rossiello R; Rienzo M; Cutillo L; Casamassimi A; de Nigris F; Schiano C; Rossiello L; Femiano F; Gombos F; Napoli C
    J Biol Chem; 2008 Mar; 283(13):8736-45. PubMed ID: 18199752
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Critical appraisal of different triggering pathways for the pathobiology of pemphigus vulgaris-A review.
    R H; Ramani P; Tilakaratne WM; Sukumaran G; Ramasubramanian A; Krishnan RP
    Oral Dis; 2022 Oct; 28(7):1760-1769. PubMed ID: 34152662
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Validation of the commitment index of skin and mucous membranes in pemphigus vulgaris for the clinical evaluation of patients with pemphigus vulgaris.
    Souza SR; Azulay-Abulafia L; Nascimento LV
    An Bras Dermatol; 2011; 86(2):284-91. PubMed ID: 21603812
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pemphigus vulgaris presenting as esophageal ulceration. Report of an underdiagnosed manifestation.
    Leal C; Silva M; Barbeiro S; Vasconcelos H
    Acta Gastroenterol Belg; 2021; 84(2):365-366. PubMed ID: 34217189
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ocular Involvement in Pemphigus Vulgaris Without Skin Lesions: A Case Report.
    Majid I; Martel BR; Martel M; Tamura LK
    Cureus; 2022 Jun; 14(6):e26309. PubMed ID: 35911266
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pemphigus Vulgaris Successfully Treated With Bromocriptine.
    Lyadova N; Ghalichi NS
    J Drugs Dermatol; 2024 Mar; 23(3):e83-e85. PubMed ID: 38443120
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pemphigus Vulgaris: More Than Just a Skin Disease.
    Ruiz S; Puebla B; Hernandez N; Rubio V; Young E; Mir H
    Ann Plast Surg; 2023 Jul; 91(1):62-63. PubMed ID: 37450862
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral Pemphigus Vulgaris.
    Subadra K; S S; Warrier S A
    Cureus; 2021 Sep; 13(9):e18005. PubMed ID: 34671517
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Case report: Mounded and refractory keratoses (MARK), a novel presentation of pemphigus vulgaris.
    Le ST; Toussi AM; Nava JE; Downing LA; Fung MA
    Front Med (Lausanne); 2022; 9():1087382. PubMed ID: 36703899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.